Treatment of patients with non-gating mutations with potentiators Source: International Congress 2015 – Advancing therapies for cystic fibrosis Year: 2015
Tolerance and efficacy of antifibrotic treatments in IPF patients carriying telomere related gene mutations Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019
Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation Source: Annual Congress 2011 - Cystic fibrosis: detection and monitoring of early lung disease Year: 2011
Description of new CFTR gene’s mutations in patients of Russia Source: Virtual Congress 2020 – Cystic fibrosis Year: 2020
How to manage side-effects of targeted therapies? Source: Annual Congress 2010 - PG7 Postgraduate Course: How to manage treatment complications of lung cancer Year: 2010
Targeting targeted therapies: more choices and the best sequences Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018
Improved CFTR and lung function with VX-770, a novel investigational potentiator of CFTR, in subjects with the G551D-CFTR mutation Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections Year: 2010
Pattern of drug resistance among patients who fail Cat II regimen and patients who fail standard treatment: is there any difference? Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Predictive factors: can we identify patients who will benefit from a specific treatment? Source: Annual Congress 2011 - Prognostic and predictive factors in lung cancer Year: 2011
Therapeutic response in COPD patients with CFTR R75Q variant and mEPHX "slow" allele – is there a difference? Source: Eur Respir J 2006; 28: Suppl. 50, 30s Year: 2006
Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease Year: 2012
Second-line injectables: are they essential to treat MDR/XDR-TB cases? Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles Source: ERJ Open Res, 5 (2) 00082-2019; 10.1183/23120541.00082-2019 Year: 2019
Late Breaking Abstract: GRC 17536, a novel, selective TRPA1 antagonist for potential treatment of respiratory disorders Source: Annual Congress 2010 - Animal models of asthma and lung inflammation Year: 2010
Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to? Source: Eur Respir Rev 2015; 24: 375-377 Year: 2015
Carriers of a single CFTR mutation are asymptomatic: an evolving dogma? Source: Eur Respir J, 56 (3) 2002645; 10.1183/13993003.02645-2020 Year: 2020
Are KRAS mutations druggable? Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Failure of EGFR TKI treatment: mechanisms and current strategies? Source: ERS Research Seminar Year: 2015
CFTR correctors and potentiators: pre-clinical studies in mouse models for CF Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease Year: 2009
Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011